Alkermes Inc, based in Wilmington, OH, is a pharmaceutical company dedicated to developing innovative medicines for neurological and psychiatric disorders. With a focus on diseases that are complex and difficult to treat, Alkermes leverages its long-standing expertise in neuroscience to make a meaningful impact on patients' lives.
The company's research and development pipeline includes investigational candidates such as olanzapine and samidorphan for schizophrenia and bipolar I disorder, as well as ALKS 2680 for narcolepsy type 1. Alkermes is committed to driving progress in the field of neuroscience through collaboration, compassion, and a shared mission to improve patient outcomes.
Generated from the website